CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

The American Astronomical Society (AAS) has launched a new website, eclipse.aas.org [ https://eclipse.aas.org], to help prepare the country for next year’s most anticipated celestial spectacle: the ...

Vir Biotechnology, Inc.'s phase 3 ECLIPSE program for HDV, leveraging tobevibart and elebsiran, shows promise based on positive phase 2 SOLSTICE study results. The global hepatitis D market size is ...

As the United States prepares for the first total solar eclipse to race across the entire continental United States in 99 years, on August 21, 2017, Astronomers Without Borders (AWB) is launching a ...

Given that Marion and the other 34 Ohio counties will be in the path of full totality during the April 8, 2024, solar eclipse, many organizations are offering informational programs to help people ...

First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...